Vismodegib + Sonidegib
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma, Gorlin Syndrome, Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Carcinoma, Basal Cell Tumor, Skin Cancer, Neoplasm of Skin, Neoplasms, Basal Cell
Trial Timeline
Nov 1, 2021 → Dec 1, 2026
NCT ID
NCT05463757About Vismodegib + Sonidegib
Vismodegib + Sonidegib is a pre-clinical stage product being developed by Sun Pharmaceutical for Basal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05463757. Target conditions include Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma.
What happened to similar drugs?
1 of 7 similar drugs in Basal Cell Carcinoma were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05463757 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Basal Cell Carcinoma